Machine signal
Active cluster sell — 5 distinct insiders, $1.1M, window ends Sep 14, 2026.
Figures computed from official regulatory filings — .
Analysttarget 6 USD (-38%)
Ownershipinsiders 15.28% · institutions 75.7% · short 9.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for PUMA BIOTECHNOLOGY, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
32 buys292 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| WILSON TROY EDWARDtrack record | Sell | $45.5K | SEC |
| Cesano Alessandra | Sell | $567K | SEC |
| Cesano Alessandra | Exercise | $146.5K | SEC |
| Cesano Alessandra | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| AUERBACH ALAN H | Sell | $364.1K | Unusual size | SEC |
| HUNT DOUGLAS M | Sell | $69.9K | Unusual size | SEC |
| NOUGUES MAXIMO F | Sell | $77.6K | Unusual size | SEC |
| Senderowicz Adrian | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cesano Alessandra | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MILLER MICHAEL PATRICK | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dorval Allison | Sell | $83.6K | Unusual size | SEC |
| Stuglik Brian M | Sell | $58.3K | Unusual size | SEC |
| Stuglik Brian M | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WILSON TROY EDWARDtrack record | Sell | $77.7K | SEC |
| WILSON TROY EDWARDtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dorval Allison | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MOYES JAY M | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Senderowicz Adrian | Sell | $194.3K | SEC |
| MOYES JAY M | Sell | $158.8K | SEC |
| HUNT DOUGLAS M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| NOUGUES MAXIMO F | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| AUERBACH ALAN H | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| AUERBACH ALAN H | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| NOUGUES MAXIMO F | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HUNT DOUGLAS M | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |